149 completed, 27 unknown, 13 recruiting, 10 active not recruiting. 220 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 220 | Completed 149, Unknown 27, Recruiting 13, Active not recruiting 10, Terminated 8, Not yet recruiting 6, Withdrawn 6, Enrolling by invitation 1 |
Follow Osteoporosis: new trials by email Literature Review of Osteoporosis trials Research Report on Osteoporosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU - Osteoporosis in Post-menopausal Women | Phase 4 | Not yet recruiting | Sahlgrenska University Hospital | 216 | 2027-01-11 | 2026-08-19 |
| Romosozumab and Denosumab Combination Therapy for Osteoporosis Romosozumab, Romosozumab and Denosumab - Postmenopausal Osteoporosis | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 100 | 2027-01-01 | 2026-11-03 |
| Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years Romosozumab, Denosumab - Glucocorticoid-Associated Osteopenia and Osteoporosis | Phase 4 | Not yet recruiting | Tuen Mun Hospital | 54 | 2026-09-01 | 2026-08-12 |
| The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation Ibandronate IV, Zoledronic acid IV - Postmenopausal Osteoporosis, Postmenopausal Osteopenia | Phase 4 | Recruiting | National Taiwan University Hospital | 52 | 2026-08-20 | 2026-08-25 |
| Osteoporotic Fracture and Lidocaine Plaster 5% for Neuropathic Pain preventioN Lidocaine 5% medicated plaster - Osteoporotic Vertebral Fracture, Neuropathic Pain | Phase 4 | Not yet recruiting | University Hospital, Clermont-Ferrand | 30 | 2026-07-01 | 2026-07-08 |
| Step-down Therapy After Long-term Osteoporosis Treatment zoledronate, Denosumab De-escalation - Osteoporosis | Phase 4 | Recruiting | National Taiwan University Hospital | 44 | 2026-01-01 | 2025-12-15 |
| Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis Denosumab, Romosozumab - Osteoporosis | Phase 4 | Recruiting | National Taiwan University Hospital | 90 | 2025-12-03 | 2025-12-16 |
| GLP-1R Actions on Muscle and the Skeleton Tirzepatide, Lifestyle toolkit - Musculoskeletal Abnormalities, Obesity | Phase 4 | Recruiting | Pennington Biomedical Research Center | 50 | 2025-10-09 | 2026-08-27 |
| StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis a second infusion of ZOL when crosslaps levels reach 300 pg/mL, a rescue second infusion at month-12 (standard traitment) - Postmenopausal Osteoporosis | Phase 4 | Recruiting | University Hospital, Toulouse | 200 | 2025-10-02 | 2025-12-31 |
| The Effect of Semaglutide on Bone Health semaglutide combined with metformin - Osteoporosis, Osteoporosis Fracture | Phase 4 | Not yet recruiting | The First Affiliated Hospital of Xiamen University | 150 | 2025-09-15 | 2025-09-17 |
| Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients Romosozumab followed by Denosumab, Romosozumab and Denosumab Cycle Therapy - Osteoporosis, Osteoporosis Postmenopausal | Phase 4 | Recruiting | National Taiwan University Hospital | 70 | 2025-04-08 | 2026-06-23 |
| A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures Alendronate 70mg weekly - Osteoporosis in Post-menopausal Women | Phase 4 | Recruiting | Odense University Hospital | 1400 | 2025-02-21 | 2025-03-07 |
| Combined Anabolic Therapy Romosozumab, Teriparatide - Osteoporosis, Postmenopausal, Osteoporosis | Phase 4 | Recruiting | Massachusetts General Hospital | 50 | 2025-02-03 | 2026-10-08 |
| Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures Romosozumab and Denosumab Combination Therapy, Romosozumab Prefilled Syringe [Evenity], Denosumab (Prolia) - Osteoporosis in Post-menopausal Women | Phase 4 | Not yet recruiting | Marmara University | 60 | 2025-01-15 | 2024-12-27 |
| Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 Months Romosozumab, Denosumab - Osteoporosis, Glucocorticoids Toxicity | Phase 4 | Completed | Tuen Mun Hospital | 54 | 2024-08-20 | 2026-05-05 |
| Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China Prolia - Osteoporosis | Phase 4 | Active not recruiting | Amgen | 102 | 2024-08-06 | 2026-02-12 |
| Effects of First-Line Oral Hypoglycemics in Bone Markers of Treatment Naïve Saudi Adults With Type 2 Diabetes Metformin, Lifestyle - Diabetes Type 2, Osteoporosis | Phase 4 | Unknown | King Saud University | 111 | 2024-08-01 | 2024-06-03 |
| A Study on the Prevention and Treatment of GIOP With Eldecalcitol Eldecalcitol capsules, Alfacalcidol tablets, Calcium carbonate tablets - Rheumatoid Arthritis, Osteoporosis | Phase 4 | Unknown | Chinese SLE Treatment And Research Group | 314 | 2024-06-01 | 2024-04-25 |
| The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity Denosumab, Saline (0.9% NaCl) - Osteoporosis | Phase 4 | Recruiting | Aarhus University Hospital | 40 | 2024-05-21 | 2025-12-15 |
| Preserving Geriatric Muscle With an Osteoporosis Medication Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Infusion - Osteoporosis | Phase 4 | Recruiting | Chrissy Kistler | 155 | 2024-02-08 | 2026-09-23 |
Showing 20 of 220. Sign in to see all of them.
Osteoporosis, Postmenopausal (72) · Bone Diseases, Metabolic (37) · Fractures, Bone (14) · Breast Neoplasms (6) · Osteoporotic Fractures (6) · Diabetes Mellitus, Type 2 (4) · Frailty (4) · HIV Infections (4) · Hyperparathyroidism, Primary (4) · Spinal Cord Injuries (4) · Arthritis, Rheumatoid (3) · Cardiovascular Diseases (3) · Cystic Fibrosis (3) · Hypercalcemia (3)
Metabolic Diseases (220) · Musculoskeletal Diseases (220) · Nutritional and Metabolic Diseases (220) · Bone Diseases (218) · Bone Diseases, Metabolic (183) · Wounds and Injuries (30) · Pathological Conditions, Signs and Symptoms (23) · Immune System Diseases (13) · Skin and Connective Tissue Diseases (13) · Fractures, Bone (12) · Signs and Symptoms (12) · Endocrine System Diseases (11) · Nervous System Diseases (11) · Pathologic Processes (11)
Denosumab (34) · Zoledronic Acid (30) · Alendronate (29) · Teriparatide (29) · Risedronic Acid (23) · Ibandronic Acid (22) · Vitamin D (16) · Calcium (14) · romosozumab (14) · Raloxifene Hydrochloride (13) · Cholecalciferol (10) · Calcium Carbonate (5) · Diphosphonates (4) · Estradiol (4) · Kyphoplasty (4)
Eli Lilly and Company (16) · Hoffmann-La Roche (15) · National Taiwan University Hospital (9) · Sanofi (9) · Massachusetts General Hospital (8) · Tuen Mun Hospital (7) · Susan L. Greenspan (5) · University of Aarhus (5) · University of Wisconsin, Madison (5) · Aarhus University Hospital (4) · Amgen (4) · GlaxoSmithKline (4) · Charite University, Berlin, Germany (3) · James J. Peters Veterans Affairs Medical Center (3) · Medical University of Vienna (3)
United States (82) · Denmark (15) · Canada (14) · China (14) · France (13) · Spain (13) · Germany (11) · South Korea (10) · Taiwan (9) · Greece (8) · Australia (7) · Mexico (7) · United Kingdom (7) · Austria (6) · Belgium (6)
Benjamin Leder, MD (4) · Anne Kenny, MD (3) · Chi Chiu Mok, MD, FRCP (3) · Karen E Hansen, MD (3) · Steven C Kirshblum, M.D. (3) · Susan L Greenspan, MD (3) · Aasis Unnanuntana, MD (2) · Bente L Langdahl, MD PhD DMSc (2) · Bente Langdahl, MD, Professor, DMSc, PhD (2)
PMID 34231877, PMID 11138687, PMID 16018754, PMID 33813753, PMID 35478046, PMID 36088628, PMID 38979716, PMID 39527056, PMID 11063900, PMID 1421796, PMID 14742657, PMID 16490909, PMID 17182297, PMID 17355365, PMID 18039992, PMID 18077316, PMID 18539106, PMID 18641106, PMID 18682511, PMID 18838053, PMID 19246088, PMID 19291931, PMID 19474141, PMID 19584192, PMID 19671655, PMID 19929434, PMID 20200964, PMID 20204604, PMID 20578215, PMID 20722847, PMID 20835566, PMID 20863330, PMID 21187295, PMID 21261673, PMID 21289258, PMID 21347742, PMID 21400196, PMID 21703900, PMID 21796066, PMID 21877131, PMID 21912321, PMID 22235252, PMID 22326720, PMID 22350731, PMID 22354743, PMID 22443312, PMID 22848407, PMID 23048011, PMID 23327689, PMID 23446769
2005 (1), 2008 (1), 2015 (1), 2023 (1), 2025 (1), P30AG024827 (1), R01AG018887 (1), R01AG050302 (1), R01AG052123 (1), R01AG059417 (1), R01AG066825 (1), R01AG072797 (1), R01AG074979 (1), R01AR041443 (1), R01AR073191 (1)